Form D · Biotechnology
Avenzoar Pharmaceuticals, Inc.
Los Angeles, CA · CIK 0001792612
Offering snapshot reported Jun 16, 2023 · SEC filing
- Reported sold
- $900K Offering amount: $2.97M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 31, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 16, 2023 | Initial | $899,748 | No comparison | 2 | SEC filing |
| Oct 31, 2019 | Initial | $525,144 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-484484
Source: Form D, filed Jun 16, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Terrance J. Bruggeman | Director, Executive |
| Mark Chin | Director |
| Mouad Edderkaoui | Director |
| David Kramer | Executive |
| Stephen Pandol | Director |
| William Reavey | Executive |
| Shierley Widjaja | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1819 Outpost Dr.
Los Angeles, CA, 90089
Los Angeles, CA, 90089